UBS analyst Michael Yee clearly preferred Eli Lilly (LLY-1.61%) over Novo Nordisk (NVO-0.21%) in a recent discussion with CNBC. Describing Eli Lilly as a growth company and Novo N ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results